期刊文献+

抑癌基因XEDAR和LKb1在胃癌中表达及预后关系的研究 被引量:1

下载PDF
导出
摘要 目的探讨抑癌基因XEDAR和LKb1在胃癌中表达及预后关系。方法采用免疫组织化学(SP)法检测115例胃癌组织和20例胃正常组织中LKB1的表达及预后关系。结果抑癌基因XEDAR在胃癌组织中有多种表达形式,其中以低表达或不表达为主。胃癌患者黏膜组织的临床分期、淋巴转移、LAuren's分型以及患者预后与抑癌基因LKB1的表达低有关(P<0.05)。结论 XEDAR基因作为抑癌基因参与胃癌的发生和发展;胃癌组织黏膜的发展演变与LKB1的表达低有关,并且对于评估胃癌的恶性程度及其预后判断具有重要的临床参考价值。
作者 高阳 白艳红
出处 《菏泽医学专科学校学报》 2016年第1期27-28,共2页 Journal of Heze Medical College
  • 相关文献

参考文献6

  • 1夏雷,莫伏根,李刚,徐新宇.胃癌中HER-2和HER-3的表达及临床意义[J].实用老年医学,2013,27(11):903-907. 被引量:5
  • 2闫毓秀,张淑萍,滑静.p53基因研究进展[J].北京农学院学报,2009,24(2):74-77. 被引量:19
  • 3Stammberger HR,Kenney DW.Paranasal sinuse:Anatomict erminology and nomen clature[J].Ann Oto Rhinol Laryngol,2011,1 67(s u p p l):7-16.
  • 4Kountourakis P,Pavlakis K,Psyrri A,et al.Prognostic signific Ance of HER3 And HER4 protein expression in colorect Al Adenoc Arcinom As[J].BMC CAncer,2006,28(6):46.
  • 5She lbourne K D,Brue ckmann RR.Rush-pinfi Xation of supracon dylarand intercondy larfracture softhefemur[J].JBone Joint Surg Am,2010,6 4(2):161–169.
  • 6Khanma,Combscs,Bruntem,et al.Positrone mission tomography scanningin the evaluation of hepatocellul ar arcinoma[J].Ann Nucl Med,2009,14(2):121-126.

二级参考文献40

  • 1马赫,杨为民,叶章群.表皮生长因子受体Her3和Her4在膀胱癌的表达[J].临床泌尿外科杂志,2006,21(7):537-538. 被引量:1
  • 2Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells[J]. Nature , 1979,278(5701) : 261-263.
  • 3Baker S J,Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma[J]. Science, 1989,244(4901) :217- 221.
  • 4Toledo F,Wahl GM. Regulating the p53 pathway:in vitro hypotheses,in vivo veritas[J].Nat Rev Cancer, 2006, 6 (12) 909- 923.
  • 5Giaannoudis A, Herrington CS. Differential expression of p53 and p21 in grade cervical squamous intraepithelial lisions infected with low, intermediated, and high risk human papillomaviruses[J]. Cancer, 2000,89(6) : 1300-1307.
  • 6Li Y, Bhuiyan M, Vaitkevicius VK, et al. Structural alteration of p53 protein correlated to survival in patients with pancreatic adenocarcinoma[J]. Pancreas, 1999,18 (1) : 104- 110.
  • 7Tiguert R, Bianco F J, Oskanian P, et al. Structural alteration of p53 protein in patients with muscle invasive bladdert ransitional cell carcinoma[J]. J Urol,2001,166 (6) :2155-2160.
  • 8FinIay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms on hsc70-p53 complex with an altered half life[J]. Mol Cell Biol, 1988,8(2) :531- 539.
  • 9Hinds P,Finlay C,Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation[J]. J Virol, 1989,63 (2) : 739-746.
  • 10Apollonia Tullo, Anna Maria D' Erchia, Elisabetta Sbis. Methods for screening tumors for p53 status and therapeutic explication[J]. Expert Rev Mol Diagn,2003, 3(3), 289-301.

共引文献20

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部